{
  "source": "PA-Notification-Rinvoq-Rinvoq-LQ.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1292-12\nProgram Prior Authorization/Notification\nMedication Rinvoq® (upadacitinib) extended-release tablets/ Rinvoq® LQ (upadacitinib)\noral solution\nP&T Approval Date 9/2019, 9/2020, 9/2021, 2/2022, 3/2022, 5/2022, 6/2022, 12/2022, 7/2023,\n9/2023, 6/2024, 6/2025\nEffective Date 8/17/2025\n1. Background:\nRinvoq is a Janus kinase (JAK) inhibitor. Rinvoq and/or Rinvoq LQ is indicated for the treatment of:\n• Adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate\nresponse or intolerance to one or more tumor necrosis factor (TNF) blockers.\nLimitation of Use:\nThe use of Rinvoq in combination with other JAK inhibitors, biologic DMARDs, or with potent\nimmunosuppressants such as azathioprine and cyclosporine is not recommended.\n• Adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have an\ninadequate response or intolerance to one or more TNF blockers.\nLimitation of Use:\nRinvoq/Rinvoq LQ is not recommended for use in combination with other JAK inhibitors,\nbiologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.\n• Adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic\ndermatitis whose disease is not adequately controlled with other systemic drug products,\nincluding biologics, or when use of those therapies are inadvisable.\nLimitation of Use:\nRinvoq is not recommended in combination with other JAK inhibitors, biologic\nimmunomodulators, or with other immunosuppressants.\n• Adults with moderately to severely active ulcerative colitis who have had an inadequate response\nor intolerance to one or more TNF blockers.\nLimitations of Use:\nRinvoq is not recommended for use in combination with other JAK inhibitors, biological\ntherapies for ulcerative colitis, or with other potent immunosuppressants such as azathioprine and\ncyclosporine.\nRinvoq should be discontinued",
    " use in combination with other JAK inhibitors, biological\ntherapies for ulcerative colitis, or with other potent immunosuppressants such as azathioprine and\ncyclosporine.\nRinvoq should be discontinued if adequate therapeutic response is not achieved with the 30 mg\ndosage. Use the lowest effective dosage needed to maintain response.\n• Adults with active ankylosing spondylitis who have had an inadequate response or intolerance to\none or more TNF blockers.\n© 2025 UnitedHealthcare Services, Inc.\n1\nLimitations of Use:\nRinvoq is not recommended for use in combination with other JAK inhibitors, biologic\nDMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.\n• Adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation\nwho have had an inadequate response or intolerance to TNF blocker therapy.\nLimitations of Use:\nRinvoq is not recommended for use in combination with other JAK inhibitors, biologic\nDMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.\n• Adults with moderately to severely active Crohn’s disease who have had an inadequate response\nor intolerance to one or more TNF blockers.\nLimitations of Use:\nRinvoq is not recommended for use in combination with other JAK inhibitors, biological\ntherapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and\ncyclosporine\n• Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have\nan inadequate response or intolerance to one or more TNF blockers.\nLimitation of Use:\nRinvoq/Rinvoq LQ is not recommended for use in combination with other JAK inhibitors,\nbiologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.\n• Adults with giant cell arteritis.\nLimitation of Use:\nRinvoq is not recommended for use in combination with other JAK inhibitors, biologic\nDMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.\n2. Coverage Criteriaa",
    "tion of Use:\nRinvoq is not recommended for use in combination with other JAK inhibitors, biologic\nDMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.\n2. Coverage Criteriaa:\nA. Rheumatoid Arthritis (RA)\n1. Initial Authorization\na. Rinvoq will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active RA\n-AND-\n(2) History of failure, contraindication, or intolerance to at least one TNF inhibitor\n-AND-\n(3) Patient is not receiving Rinvoq in combination with either of the following:\n© 2025 UnitedHealthcare Services, Inc.\n2\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\nOlumiant (baricitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine or cyclosporine)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Rinvoq will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Rinvoq therapy\n-AND-\n(2) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\nOlumiant (baricitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine or cyclosporine)\nAuthorization will be issued for 12 months.\nB. Psoriatic Arthritis (PsA)\n1. Initial Authorization\na. Rinvoq or Rinvoq LQ will be approved based on all of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) History of failure, contraindication, or intolerance to at least one TNF inhibitor\n-AND-\n(3) Patient is not receiving Rinvoq or Rinvoq LQ in combination with either of the\nfollowing:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab),\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (",
    "immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab),\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Otezla (apremilast)]\n(b) Potent immunosuppressant (e.g., azathioprine or cyclosporine)\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n3\n2. Reauthorization\na. Rinvoq or Rinvoq LQ will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Rinvoq or Rinvoq LQ therapy\n-AND-\n(2) Patient is not receiving Rinvoq or Rinvoq LQ in combination with either of the\nfollowing:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab),\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Otezla (apremilast)]\n(b) Potent immunosuppressant (e.g., azathioprine or cyclosporine)\nAuthorization will be issued for 12 months.\nC. Atopic Dermatitis\n1. Initial Authorization\na. Rinvoq will be approved based on all of the following criteria:\n(1) Diagnosis of moderate-to-severe chronic atopic dermatitis\n-AND-\n(2) Patient is 12 years of age or older\n-AND-\n(3) History of failure, contraindication, or intolerance to at least one systemic drug\nproduct for the treatment of atopic dermatitis\n-AND-\n(4) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent\n(dupilumab), Cibinqo (abrocitinib), Xeljanz/XR (tofacitinib), Olumiant\n(baricitinib), Opzelura (topical ruxolitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\n2. Reauthorization\n© 2025 UnitedHealthcare Services, Inc.\n4\na. Rinvoq will",
    "otent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\n2. Reauthorization\n© 2025 UnitedHealthcare Services, Inc.\n4\na. Rinvoq will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Rinvoq therapy\n-AND-\n(2) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent\n(dupilumab), Cibinqo (abrocitinib), Xeljanz/XR (tofacitinib), Olumiant\n(baricitinib), Opzelura (topical ruxolitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\nD. Ulcerative Colitis (UC)\n1. Initial Authorization\na. Rinvoq will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active UC\n-AND-\n(2) History of failure, contraindication, or intolerance to at least one TNF inhibitor\n-AND-\n(3) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\nOlumiant (baricitinib), Stelara (ustekinumab), Skyrizi (risankizumab)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Rinvoq will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Rinvoq therapy\n-AND-\n(2) Patient is not receiving Rinvoq in combination with either of the following:\n© 2025 UnitedHealthcare Services, Inc.\n5\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\nOlumiant (baricitinib), Stelara (ustekinumab), Skyrizi (risankizumab)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclo",
    "poni (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\nOlumiant (baricitinib), Stelara (ustekinumab), Skyrizi (risankizumab)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\nE. Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis\n1. Initial Authorization\na. Rinvoq will be approved based on all of the following criteria:\n(1) Diagnosis of active ankylosing spondylitis or non-radiographic axial\nspondyloarthritis\n-AND-\n(2) History of failure, contraindication, or intolerance to at least one TNF inhibitor\n-AND-\n(3) Patient not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\nOlumiant (baricitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Rinvoq will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Rinvoq therapy\n-AND-\n(2) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\nOlumiant (baricitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n6\nF. Crohn’s Disease (CD)\n1. Initial Authorization\na. Rinvoq will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active Crohn’s disease\n-AND-\n(2) History of failure, contraindication, or intolerance to at least one TNF inhibitor\n-AND-\n(3) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator ",
    " History of failure, contraindication, or intolerance to at least one TNF inhibitor\n-AND-\n(3) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., adalimumab, Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nXeljanz (tofacitinib), Olumiant (baricitinib), Stelara (ustekinumab), Skyrizi\n(risankizumab)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Rinvoq will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Rinvoq therapy\n-AND-\n(2) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., adalimumab, Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nXeljanz (tofacitinib), Olumiant (baricitinib), Stelara (ustekinumab), Skyrizi\n(risankizumab)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\nG. Polyarticular Juvenile Idiopathic Arthritis (pJIA)\n1. Initial Authorization\na. Rinvoq or Rinvoq LQ will be approved based on all of the following criteria:\n© 2025 UnitedHealthcare Services, Inc.\n7\n(1) Diagnosis of active polyarticular juvenile idiopathic arthritis\n-AND-\n(2) History of failure, contraindication, or intolerance to at least one TNF inhibitor\n-AND-\n(3) Patient is not receiving Rinvoq or Rinvoq LQ in combination with either of the\nfollowing:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Olumiant (baricitinib),\nXeljanz (tofacitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Rinvoq or Rinvoq LQ will be approved based on both o",
    "otent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Rinvoq or Rinvoq LQ will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Rinvoq or Rinvoq LQ therapy\n-AND-\n(2) Patient is not receiving Rinvoq or Rinvoq LQ in combination with either of the\nfollowing:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Olumiant (baricitinib),\nXeljanz (tofacitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\nH. Giant Cell Arteritis (GCA)\n1. Initial Authorization\na. Rinvoq will be approved based on both of the following criteria:\n(1) Diagnosis of giant cell arteritis\n-AND-\n(2) Patient is not receiving Rinvoq in combination with either of the following:\n© 2025 UnitedHealthcare Services, Inc.\n8\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Olumiant (baricitinib),\ntocilizumab, Xeljanz (tofacitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Rinvoq will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Rinvoq therapy\n-AND-\n(2) Patient is not receiving Rinvoq in combination with either of the following:\n(a) Targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Olumiant (baricitinib),\ntocilizumab, Xeljanz (tofacitinib)]\n(b) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan cov",
    " azathioprine, cyclosporine, mycophenolate\nmofetil)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits, Medical Necessity, and/or Step Therapy may be in place.\n4. References:\n1. Rinvoq [package insert]. North Chicago, IL: AbbVie Inc.; April 2025.\nProgram Prior Authorization/Notification – Rinvoq (upadacitinib)/ / Rinvoq LQ\nChange Control\n9/2019 New program\n9/2020 Annual review. Minor update to background. Changed reauthorization\nduration to 12 months. Updated reference.\n9/2021 Annual review with no changes to coverage criteria.\n© 2025 UnitedHealthcare Services, Inc.\n9\n2/2022 Added step through a TNF inhibitor for RA and coverage criteria for\nPsA per updated label. Updated background and references.\n3/2022 Updated background and added coverage criteria for new indication for\natopic dermatitis. Updated references.\n5/2022 Updated background and added coverage criteria for new indication for\nulcerative colitis. Updated reference.\n6/2022 Updated background and added coverage criteria for new indication for\nankylosing spondylitis. Updated reference.\n12/2022 Updated background and added coverage criteria for new indication for\nnon-radiographic axial spondyloarthritis. Added state mandate\nfootnote. Updated reference.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples. Updated background and\nadded coverage criteria for crohn’s disease. Updated reference.\n9/2023 Updated examples. No change to coverage c",
    "ation language to targeted\nimmunomodulator and updated examples. Updated background and\nadded coverage criteria for crohn’s disease. Updated reference.\n9/2023 Updated examples. No change to coverage criteria.\n6/2024 Added Rinvoq LQ to the program. Updated criteria with pediatric\nindication for PsA. Added criteria for new indication for pJIA. Updated\nbackground and reference.\n6/2025 Updated background and added coverage criteria for new indication for\nGiant Cell Arteritis (GCA). Updated reference.\n© 2025 UnitedHealthcare Services, Inc.\n10"
  ]
}